Business Context and Reporting Period
This Form 8-K filing by Community Health Systems, Inc. (CYH) reports corporate governance changes and executive compensation approvals effective February 16, 2022. The report covers the appointment of a new Lead Director, reorganization of Board standing committees, and the establishment of 2022 compensation packages for Named Executive Officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2022 Base Salaries:
- Wayne T. Smith (Executive Chairman): $1,000,000
- Tim L. Hingtgen (CEO): $1,250,000
- Kevin J. Hammons (President and CFO): $750,000
- Lynn T. Simon, M.D. (President of Clinical Operations): $643,775
- Benjamin C. Fordham (EVP, General Counsel): $625,000
- 2022 Cash Incentive Targets: Ranging from 115% to 225% of base salary for eligible officers, with potential additional payouts for non-financial improvements and overachievement of company goals.
- Equity Awards (Effective March 1, 2022): Grants include Non-Qualified Stock Options, Time-Vesting Restricted Stock, and Performance-Based Restricted Stock. For example, the CEO received 100,000 options, 100,000 time-vesting shares, and 200,000 performance-based shares.
Material Changes
- Leadership Transition: John A. Clerico was appointed as the independent Lead Director, succeeding Julia B. North, who passed away on December 9, 2021.
- Committee Reorganization: The Board reorganized the Audit and Compliance, Compensation, and Governance and Nominating committees, including the appointment of Joseph A. Hastings, D.M.D. to the Governance and Nominating Committee.
- Executive Departure: Benjamin C. Fordham is retiring effective February 28, 2022, and is excluded from the 2022 performance incentive plan.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, market outlook, or general risk factors. However, it notes specific contingencies regarding executive compensation:
- Performance Contingencies: Performance-based restricted stock awards (granted March 1, 2022) are subject to attainment of objectives over a three-year period (2022-2024). Vesting ranges from 0% to 200% of the target grant based on performance.
- Vesting Schedules: Non-qualified stock options and time-vesting restricted stock vest ratably over three years beginning on the first anniversary of the grant date.
Investor Verification Checklist
- Verify the specific performance metrics tied to the 2022-2024 performance-based restricted stock awards.
- Confirm the final payout amounts for fiscal 2021 incentives, which are pending disclosure in the 2022 definitive proxy statement.
- Monitor the transition of the Lead Director role and the composition of the reorganized Board committees.
- Review the definitive proxy statement for the 2022 annual meeting for full details on the 2021 incentive compensation payments.